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Abstract
Adherence describes how a patient follows a medical regime recommended by a healthcare provider. Poor treatment
adherence represents a complex and challenging problem of international healthcare systems, as it has a substantial
impact on clinical outcomes and patient safety and constitutes an important financial burden. Since it is one of the
most common causes of treatment failure, it is extremely important for physicians to reliably distinguish between non-
adherence and non-response. This systematic review aims to summarize the current literature on treatment adherence
in dermatology, focusing on chronic inflammatory skin diseases such as psoriasis, atopic dermatitis and acne. A system-
atic literature search was performed using the PubMed Database, including articles from 2008 to 2018. Low treatment
adherence is a multidimensional phenomenon defined by the interplay of numerous factors and should under no circum-
stances be considered as the patient’s fault alone. Factors influencing treatment adherence in dermatology include
patient characteristics and beliefs, treatment efficacy and duration, administration routes, disease chronicity and the
disease itself. Moreover, the quality of the physician-patient relationship including physician-time available for the patient
plays an important role. Understanding patients’ adherence patterns and the main drivers of non-adherence creates
opportunities to improve adherence in the future. Strategies to increase treatment adherence range from reminder
programs to simplifying prescriptions or educational interventions. Absolute adherence to treatment may not be realisti-
cally achievable, but efforts need to be made to raise awareness in order to maximize adherence as far as possible.
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Introduction
Three different terms are used in the literature to describe to
which extent a patient’s behaviour corresponds with the advice
given by a healthcare provider: Compliance, adherence and con-
cordance.1–6 These three terms are often used interchangeably,
but they reflect different philosophies of the physician-patient
relationship.5,7 It can be difficult to accurately compare studies
on this topic, since the terminology used differs amongst
authors.
Until around 2003, the term compliance was most widely
used in the literature. Compliance implies an authoritarian,
asymmetric physician-patient relationship, in which the doctor
has the exclusive decisional power. Physicians give instructions
and patients are passive recipients and should follow the
prescribed regime without deviation. The word compliance may
have negative connotations as it requests a submissive and obe-
dient patient.8,9
The concept of an appropriate physician-patient relationship
has substantially changed in the last years, since patients have
gained more autonomy. This paradigmatic shift is reflected by
the new term adherence,10 which is nowadays preferably used.11
The concept of adherence is based on a partnership between
physician and patient, where both parties are actively involved in
finding a mutual treatment agreement.12,13
The word concordance, which originated in British literature,
goes even further and places the patient in the centre of the deci-
sion-making process. It focuses less on compliance and more on
overall success of treatment as a shared goal.12,14,15
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In this review article, only the term adherence will be used.
Adherence can be divided into primary and secondary adher-
ence. Primary adherence describes pharmacy refill records,
whereas secondary adherence means the correct administration
and continuation of a prescribed treatment.16
Poor treatment adherence is a complex and challenging prob-
lem of international healthcare systems, as it not only compro-
mises patients’ safety, but also constitutes a substantial financial
burden. The annual costs related to medication non-adherence
are estimated to range from 100 to 290 billion US$ in the United
States17 and approximately 1.25 billion € in Europe.18 In the era
of cost-effectiveness, the research interest in this field has dra-
matically increased. Studies have shown a median adherence rate
of 50% among patients with chronic illnesses.1,8,19 This alarming
number illustrates the importance of reliably distinguishing
non-adherence from non-response, because ‘drugs don’t work
in patients who don’t take them’.19–21 Non-adherence represents
one of the most common causes of non-response to medica-
tion,22,23 and is frequently mistaken as drug failure when insuffi-
cient care is devoted to assessing patients’ adherence to
treatment. This wrong assumption may lead the physician to
unnecessarily modify treatment or increase medication dose.
Therefore, treatment adherence plays an essential role in the out-
come of medical care.
Aims
Although the impact of treatment adherence has been exten-
sively studied for chronic diseases including hypertension,24,25
diabetes mellitus,26 epilepsy27 and HIV,28 there are only few
studies addressing this topic in dermatology. Here, we review
systematically the current literature on treatment adherence in
chronic inflammatory skin diseases such as psoriasis, atopic der-
matitis and acne.
Methods
Using the PubMed database, a literature search was conducted
to identify clinical studies and review articles that assessed treat-
ment adherence in chronic inflammatory skin disease. Specifi-
cally, we analysed reported methods used to measure adherence,
factors influencing adherence and strategies used to improve
treatment adherence. The research was limited to English,
French or German language articles published between 2008 and
2018. The following keywords were used to perform the litera-
ture search: [compliance (TI) OR adherence (TI) OR non-
adherence (TI)] AND (psoriasis OR atopic dermatitis OR acne).
Articles were selected when they covered at least one of the
topics of interest in above-mentioned diseases. Figure 1 shows
the exact flow chart of the literature search.
Measurement of treatment adherence
There is no gold standard for measuring treatment adherence. It
can be very difficult to accurately quantify a patient’s adherence,
which is why the number of unrecorded cases of non-adherence
is probably high. Table 1 summarizes available methods for
assessing treatment adherence. Traditional methods consist of
patient reports, medication logs, diaries and questionnaires.
These subjective methods are most commonly used among clini-
cians and tend to overestimate treatment adherence, as they lar-
gely rely on patients’ memory and honesty.29–31
Pill counts and weight-based measurements of topicals are
also frequently used methods,32 especially in clinical trials.
Despite the fact that these methods are practical and relatively
inexpensive, they have their limitations. Pill counts do not nec-
essarily reflect pills actually taken by the patient, one example
being untaken pills discarded prior to the physician-visit.33
Pharmacy refill records can provide information on primary
treatment adherence, but do not deliver information on
day-to-day adherence.34
A further method used to measure treatment adherence relies
on drug level assays using chemical and biological markers.
These markers may be susceptible to misinterpretation. As it has
been demonstrated that treatment adherence increases in the last
few days before a scheduled physician-visit,35 valid drug concen-
tration on the day of the visit should not unconditionally be
considered as a daily steady-state drug concentration.2 Interindi-
vidual variations in drug metabolism may also influence this
type of adherence measurement. Furthermore, for dermatologic
treatments which often include topical agents, adherence is not
routinely measurable by blood tests.
In the last decade, electronic monitoring devices have become
more and more popular and claim to be a more precise and reli-
able method for measuring treatment adherence. Medication
Event Monitoring Systems (MEMS) look like standard medica-
tion bottles, but have microprocessors in their caps which record
the date and time at which they are opened.8,36,37 MEMS can
also be utilized for monitoring topical therapy.31 In an 8-week
psoriasis clinical trial, patients were told they would be moni-
tored using diaries. In reality, adherence was also assessed with
electronic monitors. Adherence was approximately 55% when
determined by electronic monitors and 90% when determined
by self-reported diaries.38 This strongly suggests that traditional
adherence measurements significantly overestimate patient
adherence.38 Drawbacks of the MEMS are the high production
costs and the fact that they are not reusable.37,39 Moreover,
opening a bottle does not necessarily proof the consumption of
the medication under study.
Factors influencing treatment adherence
Treatment adherence is multidimensional and affected by the
interplay of factors that can be grouped into four categories:
patient-related, treatment-related, disease-related and physician-
related. Table 2 gives an overview of relevant factors that influ-
ence treatment adherence. Figure 2 shows the settings of optimal
treatment adherence.
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Patient-related
Patient-related factors are of demographic, socioeconomic and
psychological nature. Higher adherence was observed in patients
who were married, employed, educated and did not smoke or
drink.9,40,41 Age and gender also influence patient adherence,
with very young or old male patients being more likely to show
poor treatment adherence.15,40–42 Non-adherence in children
and elderly patients could possibly be associated with a lack of
autonomy, understanding or memory. Social support by family
members, friends or support groups is associated with higher
adherence rates.14 Treatment adherence declines in the presence
of circumstantial barriers including distance to the clinic and
physical handicaps.2 Higher adherence rates were observed in
patients with excellent knowledge about their disease and treat-
ment. On the other hand, misinformation or conflicting infor-
mation from another physician or from the Internet can result
in non-adherence.2,9
Unrealistic treatment expectations, doubts about treat-
ment necessity and the fear of side-effects are frequent causes
of treatment non-adherence in chronic skin diseases.43
Corticophobia is a very common phenomenon and has a sig-
nificant impact on adherence. The prevalence of topical corti-
cophobia in patients with atopic dermatitis ranges from 21%
to 84%.44 Topical corticosteroid resistance may partially be
due to non-adherence because of corticophobia.45 Self-admi-
nistered questionnaires, like the TOPICOP,46 can be helpful to
assess patients affected by topical corticophobia. Its occurrence
can be minimized if physicians explain the necessity and the
benefits of the treatment, emphasizing the fact that topical
steroids do not have systemic effects when used in the correct
way.
A very important and often underestimated patient-related
factor is mental health. In fact, psychiatric disorders like depres-
sion and anxiety have been demonstrated to be significant risk
factors for non-adherence.47–49 This finding is highly relevant, as
the prevalence of psychiatric illnesses among dermatological
patients ranges from 25% to 43%.2,47
Lastly, patients simply forget to take their medication, forget
the instructions on how to take them or lack the motivation to
carry on with their treatment.50
Articles identified by PubMed:
• Electronic search n = 168
• Manual search n = 6
Potentially relevant articles
n = 174
Articles subject to abstract 
review
n = 78
Full articles retrieved for 
detailed analysis
n = 45




Identified through in-text citations 
n = 12
Articles excluded based on title, n = 96:
• Duplicates removed n = 11
• Not  focusing on the selected skin 
diseases n = 34
• Topics of interest not met n = 51
Articles excluded based on abstract, n = 45: 
• No abstract available n = 1
• Topics of interest not met n = 44
Articles excluded based on full-text, n = 6:
• Full-text not available n = 3
• Removed because of poor quality n = 3
Figure 1 Flow chart of the paper selection process. n, number of articles.
Table 1 Methods of measuring treatment adherence
Subjective methods Semi-objective methods Objective methods
Patient reports and diaries
Patient questionnaires
Medication logs
Pill counting and tube weight measurements
Pharmacy refill records
Drug level assays
Medication Event Monitoring Systems (MEMS)
MEMS, Medication Event Monitoring Systems.
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Treatment-related
The administration route (topical, oral, subcutaneous, intra-
venous) is a very important treatment-related factor and has
been analysed in many studies.34,51–55
Topical therapies are the cornerstone of treatment in derma-
tology. One of their benefits is that they bring the pharmacologi-
cal agent precisely to the affected area, whilst limiting systemic
effects. On the other hand, their use can be time-consuming,
messy, non-esthetical and difficult to apply. In a study assessing
adherence to topical medication in patients with skin disease, the
overall adherence was 53% in patient reports and only 6% when
measured with MEMS. In average, only 35% of the prescribed
doses were used and 95% of the patients were underdosed.51
Patients often consider topical products as minor, not very effec-
tive treatments and therefore do not use them regularly.
It has been shown that adherence is better for oral than for
topical therapy.56,57 In a study analysing a newly prescribed
medication in 322 patients with different dermatologic condi-
tions, pharmacy records revealed that 86% of oral agents com-
pared to only 65% of topical agents were filled.34 In patients
with acne, the adherence to oral retinoids was 57%, whereas to
topical retinoids only 2%.54
Biologic agents have shown relatively good adherence rates,
ranging from 58% to 100%,52,58–60 which is higher than the
adherence rates reported for oral therapy.61 In two trials includ-
ing only psoriasis patients, ustekinumab showed the best overall
adherence rate among systemic therapies studied (acitretin,
methotrexate, adalimumab, etanercept, infliximab).62,63 Com-
paring the adherence rates of different anti-tumour necrosis fac-
tor alpha agents, infliximab had better results than adalimumab
and etanercept.59 These differences could rely on the fact that
infliximab is administrated intravenously and has to be given by
a healthcare professional, whereas adalimumab and etanercept
can be self-administrated by the patient.64 Chan et al. evaluated
the impact of the administration route on adherence in a trial
with 106 psoriasis patients. The self-reported adherence rates
were 100% for biologic therapies, 96% for oral therapy, 93% for
phototherapy and 73% for topical therapy.52 In fact, patients
often affirm that they would prefer to take a pill or get an injec-
tion, than to apply topical agents.9
Treatment duration, dosing frequency, regime complexity
and pill burden have an impact on patient adherence.41 Pill bur-
den is defined as the total number of pills (tablets or capsules)
that a patient takes on a daily basis.65,66 It has been shown that a
high pill burden negatively affects treatment adherence.66–69 The
same goes for topical treatments; however, there is no estab-
lished term to describe how many creams or ointments a patient
applies per day. In a MEMS-controlled acne study, a once daily
combination product showed better adherence rates and better
efficacy than daily application of the same two pharmacological
agents separately.8,70 A study analysing the effect of treatment
duration on adherence in patients with eczema, reported an
adherence to topical tacrolimus of 96% at week 1, 64% at week 3
and only 42% at week 12.71
Side-effects, like skin irritation or dryness, are common causes
of non-adherence.41,47,50 Treatment efficacy is another very
important treatment-related factor. Unrealistic treatment expec-
tations or the ignorance of the chronicity of a disease may lead
to the assumption of an ineffective treatment, which can result
in non-adherence.50
A commonly cited reason for non-adherence to dermatologic
treatment is the high financial impact.41 Especially, the cost of
Table 2 Factors influencing treatment adherence in chronic inflammatory skin diseases
Patient-related Treatment-related Disease-related Physician-related
 Age  Administration route (topical, oral, s.c., i.v.)  Longevity/Chronicity  Physician-patient-relationship
 Gender  Dose  Impact on QoL  Empathy
Marital status  Dosing frequency  Severity  Communication
 Socioeconomic status  Duration (long-term, short-term)  Visible lesions (e.g. facial lesions)  Patient education
 Education level  Complexity  Quantity of lesions  Patient empowering
 Employment status  Efficacy  Involved BSA  Setting the right goals
 Drinking patterns  Tolerability (e.g. side-effects, cosmetic acceptability)  Disease itself  Trust level
 Smoking status  Vehicle (e.g. creams, ointments, solutions)  Time for each patient
 Social support  Time-consumption  Frequency of follow-up visits
Mental health  Previous treatment
 Practical barriers (e.g. distance to clinic, physical handicap)  Financial burden
 Understanding of disease and treatment  Interference with patient’s lifestyle
 Treatment concerns (e.g. fear of side-effects)
 Treatment expectations




BSA, body surface area; e.g., example given; i.v., intravenous; QoL, quality of life; s.c., subcutaneous.
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topical preparations can be very important, since these are fre-
quently not covered by health insurance.72 Patients report not
having filled their prescription because of cost issues and using a
cream more sparsely than advised in order to postpone the pay-
ment for refills.73
Disease-related
The most frequently examined disease-related factor is the
chronicity of a skin disease. Patients with acute illness are much
more likely to adhere to treatment than patients with chronic ill-
ness. In a prospective study with 322 patients, primary and sec-
ondary non-adherence was much higher in chronic skin
diseases, such as atopic dermatitis and psoriasis, as compared to
acute skin diseases like infections.34
Most skin diseases have visible lesions that can cause stigmati-
sation and isolation, leading to a significant deterioration of the
quality of life (QoL). Skin diseases with only mild impact on
QoL are associated with poor adherence, whereas skin diseases
with moderate reduction of QoL are associated with a better
treatment adherence.74,75 Paradoxically, however, diseases with a
severe alteration in QoL and high disease severity show the worst
adherence.74,75 A study in psoriatic patients, examining the
impact of lesion location on adherence, found a positive
correlation between facial lesions, increasing number of lesion
sites, involved body surface area (BSA) and poor treatment
adherence.41,76 Although the psychological background of these
findings is poorly understood, embarrassment and shame could
play an important role.
Only very few studies have examined the differences in
treatment adherence between different chronic inflammatory
skin diseases, especially psoriasis and atopic dermatitis. Most
clinical trials have focused on one disease only.38,54,73,77–86 Dif-
ferent definitions and measurement methods for adherence
make it very difficult to compare them accurately. Table 3
gives an overview of adherence rates to topical and systemic
therapy in psoriasis and atopic dermatitis patients. Storm et al.
used pharmacy records to analyse primary adherence rates in
a total number of 322 patients with psoriasis, eczema and
acne. Psoriasis patients showed a primary adherence of 56%
and took in average 17 days to redeem their prescriptions. In
eczema and acne patients, primary adherence was 70 and 91%
and time to redemption was 1 and 0 days.34 One study analys-
ing adherence in chronic skin diseases, reported a tendency of
patients with psoriasis, prurigo or bullous skin diseases to
have the lowest adherence rates among chronic skin diseases.87
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Figure 2 Settings for an optimal treatment adherence in chronic inflammatory skin disease. Figure 2 shows patient-related, treatment-
related, disease-related and physician-related circumstances for an optimal treatment adherence in chronic inflammatory skin disease.
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topical agents in patients with atopic dermatitis ranged
between 32% and 100%,53,88–91 in psoriasis patients between
27 and 75%.38,41,52,56,92–94 Adherence to oral prednisolone
therapy in patients with moderate to severe hand dermatitis
was 85%.71 Adherence to oral therapy in psoriasis patients
ranged from 62% to 96%.52,55,62 Since only few studies with
inconsistent results are published, the significance of the
reported differences in adherence between chronic inflamma-
tory skin diseases remains unclear. However, there is a ten-
dency towards better adherence in atopic dermatitis patients
compared to psoriasis patients. This topic needs to be further
analysed in future studies, in order to define which patients
should most closely be monitored for treatment adherence.
Physician-related
A paternalistic relationship between physician and patient
does not usually promote treatment adherence.19 On the con-
trary, patients should be considered as independent partners
with the goal of reaching mutual agreement. When patients
feel included in the decision-making process of their treat-
ment, they are more likely to adhere to it.9,12 Open commu-
nication and empathy are the cornerstones of a good
physician-patient relationship. Physicians need to develop
reliable teaching skills, in order to properly educate their
patients about the disease and the recommended treat-
ment.1,95 In this context it is very important not to use a
medical terminology, but to adapt to patients’ vocabulary.
Inadequate assumptions about patients’ baseline level of
knowledge can lead to misunderstandings and are common
causes of non-adherence.2 In particular, for patients with
chronic skin diseases, it is very important to set the right
treatment goals, namely controlling symptoms, rather than
healing the disease.81 Furthermore, it is very important to
take enough time to listen to patients’ needs and concerns.
In fact, the trust level of a patient in his physician is a signif-
icant predictor for treatment adherence.96 Thom et al.
prospectively analysed the association between patients’ trust
in their physician and adherence to treatment. In the highest
trust category, 62% of patients followed their physicians’
recommendations, compared to 14% in the lowest trust
category.96
Strategies to improve treatment adherence
Since non-adherence can lead to treatment failure, it is crucial to
elaborate strategies to improve adherence. Because there is no
single solution that works for every patient, the best approach
may be to combine several strategies. Figure 3 summarizes dif-
ferent strategies to optimize treatment adherence.
Reminder programs using e-mails, phone calls, text messages
or smartphone applications can be helpful to counteract
patients’ forgetfulness.97 The success rate of these programs in
improving adherence is, however, inconsistent according to the
literature, and depends on patients’ character and personal-
ity.16,56,98,99
Simplifying treatment regimes and reducing pill burden are
easy methods to enhance treatment adherence. Once-daily
regimes with combined pharmacological agents are preferable,
since they are more manageable for the patient. The treatment
should be tolerable and individually tailored to each patient’s
lifestyle. Especially for topical treatments, physicians should
select vehicles according to patients’ personal preferences.97,100
A survey study of 120 patients with psoriasis showed that
patients preferred creams to ointments,40 probably because
they are less messy and take less time to be absorbed. The
affected body area also plays an important role when choosing
the right vehicle for a topical agent. For example, foams and
solutions are more suitable for application to the scalp than
creams and ointments.101
Physicians should also be conscious about the financial bur-
den of their prescriptions and should consider providing gener-
ics, if equally effective. There is no better way to ensure that a
patient will not take his medication than prescribing a too
expensive medication, which is not reimbursed.
Since oral, subcutaneous and intravenous therapy are associ-
ated with better adherence rates than topical therapy,57 physi-
cians should weigh the risks of a more invasive treatment against
the risks of non-response to treatment due to non-adherence.49
Scheduling early follow-up visits has also proven to increase
treatment adherence, according to what Feinstein calls ‘the
white-coat-compliance’.35,102 Especially, in the early stages of a
treatment, additional visits can be helpful to establish a solid
Therapeutic 
patient education
(written action plans, 
































Figure 3 Strategies to improve treatment adherence.
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treatment routine and could possibly result in fewer overall-vis-
its.16 In a study evaluating patients with psoriasis, atopic der-
matitis and hand dermatitis, optimal adherence was found
2 days before and 2 days after a physician-visit.51 Furthermore,
additional visits give the physician the opportunity to discuss
potential questions with the patient, evaluate treatment efficacy
and closely monitor side-effects. In some countries insurance
issues limit the ability of physicians to frequently control their
patients. The above measures can, however, help to build a
strong bond with the patient and to reinforce his feeling of
safety.38,88 Short-term treatment goals can seem less oppressive
and more realistically achievable, which is why it is recommend-
able to set new goals after each visit.
Adequate patient education plays a key role in ensuring opti-
mal treatment adherence. In fact, helping the patient to under-
stand his disease can empower and motivate him to take
responsibility for treatment outcome. Therapeutic patient edu-
cation (TPE)103 has been shown to increase treatment adherence
and outcome in chronic inflammatory skin disease.15,104–106 In a
randomized controlled multicentre study, Heratizadeh et al.107
showed that adult patients with atopic dermatitis educated in a
12-h multidisciplinary training programme including dermato-
logical, nutritional and psychological aspects had a significant
improvement in their coping behaviour, QoL and disease sever-
ity after 1 year of follow-up. Similarly, Reich et al.108,109 devel-
oped the Topical Treatment Optimization Programme (TTOP),
an educational and supportive intervention for psoriasis
patients. In a 64-week clinical trial with 1790 psoriasis patients, a
significantly better clinical outcome was reported in patients
randomized to TTOP as compared to standard care.108 In paedi-
atric and elderly patients, TPE should include both parents and
caregivers. Moreover, TPE in small patient groups has been
shown to maximize educational benefits and encourage
exchange of knowledge and experiences.107 In this context, the
use of drawings, photographs and videos can be helpful.9 Writ-
ten action plans can also be beneficial to address forgetfulness
and emphasize the treatment details.110 Especially, for topical
therapy, inexact dosing instructions should be avoided since they
leave too much room for individual interpretation.
Another way of promoting patient adherence is to maximize
placebo and minimize nocebo effects. Placebo and nocebo effects
describe positive and negative treatment effects that rely exclu-
sively on patients’ expectations and beliefs about treatment out-
come.111 For example, physician’s emphasis on the effectiveness
of a treatment can improve its outcome.112 On the contrary,
emphasis on possible side-effects can result in a nocebo effect
and significantly decrease the outcome.113 A meta-analysis inves-
tigated the magnitude of the placebo effect on itch in patients
with psoriasis, atopic dermatitis and urticaria. Patients were told
that they would get a potent antipruriginous drug. Even in
patients blindly randomized to placebo, itch significantly
reduced by 24%.114 Physicians should systematically make use of
placebo effects and wherever possible consciously avoid nocebo
effects, but without withholding important safety information,
in order to maximize treatment adherence and consequently
efficacy.
Last but not least, the importance of open and explicit
patient-information concerning treatment adherence should
not be underestimated. Patients are often not aware of their
poor adherence and its consequences, and ignore means to
improve it.
Outlook and conclusion
Treatment adherence is key for treatment outcome, especially in
dermatology. Nevertheless, the significance of adherence and the
need to focus on adherence research has only recently been
realized.
New technologies are currently available for more accurate
measurement of treatment adherence. Despite this, the majority
of clinical trials in dermatology are still based on subjective meth-
ods such as medication logs and weights measurements. It can be
assumed that non-adherence rates are higher than recorded, jeop-
ardizing the reported treatment efficacy rates. This implies that
much larger sample sizes are required in trials to achieve statistical
significance.115 Another limitation of most studies on adherence
in dermatology is the absence of differentiation between the dis-
tinct phases of treatment adherence, as usually only an overall
adherence rate is reported.16 Specification of which adherence
phase is being analysed is needed, and could address the fulfilment
of the prescription, the dosage, the frequency of dosing, or the
treatment duration. The literature lacks qualitative studies on
treatment adherence, in particular in dermatology. Implementing
objective measurements of adherence like MEMS and specifying
the precise phases of treatment adherence considered would add
value to future clinical trial publications.
While there is so much effort and funding going into the
development of new drugs, it is equally important to improve
the adherence to drugs that are already on the market, in order
for them to reach their full therapeutic potential. Understanding
the complex causes of non-adherence in the dermatologic
patient creates opportunities to improve adherence in the future.
This would not only benefit our patients because of better treat-
ment outcomes, but would also represent an extraordinary
reduction of healthcare costs.
This review showed that physicians should, in order to maxi-
mize treatment adherence, take enough time for their patients
and listen to their patient’s needs and concerns. However, this
constitutes a major challenge in times of increasing economic
pressure on the medical system, which forces physicians to
increase their patient turnover. Furthermore, current physician
financing systems remunerate interventional procedures better
than time taken to speak with a patient.
It is also important to bear in mind that patients vary in their
willingness and ability to adhere to a treatment. Poor adherence
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frequently comprises drug omissions and drug holidays.116
Besides improving adherence, the use of ‘forgiving pharmaceuti-
cals’37 could be another possibility to increase treatment out-
come in selected patients. ‘Forgiving pharmaceuticals’ are drugs
with long duration of action, providing solid steady-state drug
concentrations. They are therefore less affected by missed
dosages and intermittent dosing patterns. A downside of these
long-acting drugs is that they may be more susceptible for over-
dosing and adverse events.37,117
Finally, in order to progress, continuous efforts need to be
made to raise awareness about the high prevalence, causes and
consequences of poor treatment adherence. Absolute adherence
to treatment may not be realistically achievable, but we should
emphasize on its importance in order to maximize adherence as
far as possible.
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